Speedskater Erin Jackson, who won a gold medal at the 2022 Beijing Winter Olympics, talks about how eczema has affected her, ...

Sanofi stock jumped early Friday on better-than-expected third-quarter sales and earnings, and a strong showing from Dupixent ...

Treatment for chronic hives lasting at least 6 weeks may include one or more types of medication, as well as certain ...

There are some 40 interleukins that play a wide variety of roles in inflammation and the body’s immune response, some of them hitting the accelerator and others tapping the brakes. When it comes to ...

Dupixent (dupilumab) has been a breakthrough treatment for people with severe eczema, asthma, and other inflammatory ...

When you start a medication like Dupixent (dupilumab), you expect relief from eczema or asthma, not the devastation of a cancer diagnosis. Yet ...

Phase 3 data to be presented at ACAAI demonstrate Dupixent significantly reduced key nasal signs and symptoms including sinus opacification, ...

Dupixent is prescribed to asthma patients as well as for treatment of chronic obstructive pulmonary disease (COPD), chronic sinusitis, nasal polyps, eosinophilic esophagitis, and moderate to severe ...

Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions ...

Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with nasal polyps (CRSwNP), a second biologic therapy has broken through with a ...

Investing.com -- Sanofi reported stronger-than-expected third-quarter results, driven by accelerating demand for its blockbuster drug Dupixent and a wave of new product launches. Shares rose around 3% ...